The upcoming week presents earnings from key banking giants. Read here for upcoming IPOs, investor days, earnings reports, and conference presentations.

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and ...

The 90-day pause in tariffs temporally slowed the bloodbath with stocks it is too soon to consider a recovery rally.  Several ...

Researchers reported a shared genetic susceptibility of psoriasis and hidradenitis suppurativa, highlighting a need for ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

With a range of treatments available for presbyopia, the challenge for clinicians is to guide patients toward the most ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the ...